Adam Hall, Ph.D., isn’t kidding when he says the research he does is on a very small scale. But he is understating things more than just a little.
Hall works in nanomedicine, a relatively new but rapidly developing branch of nanotechnology – the study, development and application of materials between 1 and 100 nanometers in size – that is devoted to the diagnosis and treatment of disease.
What exactly is a nanometer?
It’s exactly one-billionth of a meter. A meter is 3.28 feet, or 39.37 inches, so a nanometer is 0.0000003937 of an inch. That means there are 25,400,000 nanometers in an inch.
In perhaps more understandable terms, a sheet of paper is about 100,000 nanometers thick and a typical human hair is roughly 80,000 nanometers wide. A strand of human DNA, conversely, is around 2.5 nanometers in diameter. Which is way past very small.
“Technology, in the broadest sense, has evolved to the point where we can look at things closer and closer and effectively work with smaller and smaller amounts of stuff,” said Hall, an assistant professor of biomedical engineering at Wake Forest School of Medicine, which is part of Wake Forest Baptist Medical Center.
“Ultimately, for cancer and other diseases that we worry about, the root causes are molecules. People may talk about malfunctioning cells, but what happens inside those cells to make them dangerous happens at the molecular level. That’s at the nanoscale, and that’s why we’re working there.”
Hall’s research is on the diagnostic side of nanomedicine and is centered on nanopores – nanoscopic holes in synthetic membranes through which individual molecules can be threaded. As the molecules pass through, a nanopore in an electrically charged membrane can “read” information about them by measuring changes in the flow of current.
Using a nanopore device with a pore less than 10 nanometers wide, Hall and colleagues have developed a methodology capable of detecting and counting specific DNA and RNA sequences, including those of microRNA, a class of nucleic acid no more than 10 nanometers long and a single nanometer wide that can be a biomarker of disease.
“MicroRNAs are very tiny pieces of nucleic acid that carry genetic messages and are floating through your bloodstream all the time,” Hall explained. “But if the cells producing them are diseased, whether from cancer or something else, the RNAs they release can act like messages in bottles, indicating the presence or progression of the disease.”
Hall first successfully demonstrated his methodology with a microRNA known to be an indicator of lung cancer, and he is confident that the fast, noninvasive diagnostic process, potentially requiring only a tiny blood sample, will work just as efficiently in detecting the presence – or absence – of other diseases.
“It’s a modular technique that can be applied to a whole bunch of different targets,” he said. “As long as we know the sequence of a nucleic acid that’s linked to a certain disease, we can seek out those particular molecules so only they will produce a signal that we can record when they pass through the nanopore.”
Wake Forest Baptist recently a $75,000 grant from the North Carolina Biotechnology Center in support of Hall’s efforts using the nanopore device to detect viruses responsible for infectious diseases. But Hall has no intention of stopping there. He believes his nanopore technique can also be adapted to recognize pathogenic bacteria and key genomic DNA sequences, or detect multiple distinct sequence biomarkers in tissue and biological fluids. Eventually, he hopes to develop the technology into a commercial device that will fit in the palm of a hand.
In a different Wake Forest School of Medicine lab, Nicole Levi-Polyachenko, Ph.D., an associate professor of plastic and reconstructive surgery, is working in a different area of nanomedicine, specifically with a nanoparticle created to both locate and destroy diseased cells.
“What it does is detect and treat,” she said. “But I like to think of it as trap and zap.”
The nanoparticle, which is less than 100 nanometers in diameter, contains two semiconducting polymers – one fluorescent, one heat-generating – originally designed for solar energy applications by Wake Forest University’s Center for Nanotechnology and Molecular Materials that have been modified by Levi-Polyachenko for medical use.
These two polymers are “wrapped” in a coating that directs the nanoparticle to attach itself to a specific type of cell. The fluorescent polymer can identify the targeted cells by lighting up when exposed to colored light, and the thermal polymer can destroy those cells by heating up upon exposure to infrared light.
“There are limitations with some imaging techniques so physicians often have to rely on sight and feel to determine what tissue needs to be removed, and it can be hard to tell what’s diseased and what’s not,” Levi-Polyachenko said. “What we want is a way of detection that’s extremely precise, and with the nanoparticle what’s diseased lights up and what isn’t doesn’t.
“As for treatment, the goal is to destroy the diseased tissue while saving as much healthy tissue as possible. Surgery may involve the removal of some healthy tissue, and treatments like chemotherapy affect both diseased and non-diseased cells. But these nanoparticles only attach to the targeted cells and when they’re heated up, they kill just those cells and they kill them for good. There’s no collateral damage.”
Working in animal model, Levi-Polyachenko’s research team has successfully demonstrated the nanoparticle’s ability to locate and destroy colorectal cancer cells. Current research is targeting breast cancer cells and harmful bacteria. If all continues to go well, Levi-Polyachenko said, the two-polymer nanoparticle could be approved for use in humans within 10 years.
“We’re really not all that far off,” she said.
Learn more: Nanomedicine Researchers Target Disease at the Molecular Level
The Latest on: Molecular biomarkers
[google_news title=”” keyword=”molecular biomarkers” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Northwell opens $3.2M molecular diagnostics laboratoryon May 9, 2024 at 7:05 am
The 2,800-square-foot facility is designed to identify targeted cancer therapies. Northwell said that the lab will enhance the ability to accurately diagnose and provide a prognosis for cancer ...
- Strictly no dancing: Researchers discover 'new molecular design rules'on May 8, 2024 at 8:51 am
Since the discovery of quantum mechanics more than a hundred years ago, it has been known that electrons in molecules can be coupled to the motion of the atoms that make up the molecules. Often ...
- Exploring associations between NMR-measured biomarkers and accelerated aging in cardiac catheterization patientson May 7, 2024 at 9:52 pm
A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 8, entitled, "Associations among NMR-measured ...
- Study reports on inflammatory, metabolic biomarkers and accelerated aging in cardiac catheterization patientson May 7, 2024 at 1:46 pm
A new research paper titled "Associations among NMR-measured inflammatory and metabolic biomarkers and accelerated aging in cardiac catheterization patients" has been published in Aging.
- Association of inflammatory and metabolic biomarkers and accelerated aging in cardiac catheterization patientson May 6, 2024 at 4:59 pm
A new research paper was published in Aging, entitled, “Associations among NMR-measured inflammatory and metabolic biomarkers and accelerated aging in cardiac catheterization patients.” ...
- Diagnosed With Non-Small Cell Lung Cancer? Here’s Why You Need Biomarker Testingon May 6, 2024 at 11:46 am
Biomarker tests can help your doctor learn more about the type of lung cancer you have and the best way to treat it.
- Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis and—eventually—treatmenton May 6, 2024 at 10:06 am
A new study led by University of Michigan Health Rogel Cancer Center researchers identifies novel biomarkers in renal cell carcinomas. The researchers' integrative analysis of comprehensive ...
- UB’s new mass spectrometer can accelerate discoveries of new drug targets and biomarkerson May 6, 2024 at 8:25 am
State-of-the art equipment arrived at the University at Buffalo Center of Excellence in Bioinformatics and Life Sciences (CBLS) last fall.
- New Day Aims to Enter CRC Screening Market With Combined PCR, Immunoassay Teston May 6, 2024 at 5:55 am
The Tennessee-based firm is combining molecular and protein testing technologies that it brought under one roof in a pair of deals last summer.
- Gene Profiling Enhances ACD Diagnosis in Active Dermatitis Lesionson May 3, 2024 at 4:59 am
The following is a summary of "Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitis," published in the May 2024 issue of Dermatology by Lefevre, et al.
via Google News and Bing News